Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiation dose response for subclinical metastases

H R Withers1, R Suwinski

  • 1Centre of Oncology, UCLA Medical Center, Los Angeles, CA, Poland.

Seminars in Radiation Oncology
|June 20, 1998
PubMed
Summary

Adjuvant therapy for subclinical metastases traditionally used high radiation doses. Lower doses may be effective, especially when initiated early, improving outcomes and normal tissue tolerance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Efficacy and Tolerance of Radical Radiotherapy and Radiochemotherapy in Treatment of Locally Advanced, Unresectable Rectal Cancer.

Technology in cancer research & treatment·2022
Same author

Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.

British journal of cancer·2015
Same author

Stereotactic radiotherapy (SBRT) as a sole or salvage therapy in non-small cell lung cancer patients.

Neoplasma·2011
Same author

Time factor and treatment strategies in subclinical disease.

International journal of radiation biology·2003
Same author

[Radiobiologic basis for using 131I to treat patients with thyroid cancer].

Wiadomosci lekarskie (Warsaw, Poland : 1960)·2002

Area of Science:

  • Oncology
  • Radiation Oncology
  • Cancer Biology

Background:

  • Adjuvant therapy for subclinical metastases has historically relied on empirical approaches.
  • High radiation doses (45-50 Gy) were considered necessary for effective control of subclinical lymph node involvement.
  • The development of these therapies largely ignored biological factors of micrometastases.

Purpose of the Study:

  • To re-examine assumptions about the biology of subclinical metastases.
  • To evaluate the role of treatment response in guiding adjuvant therapy development.
  • To assess the impact of dose and timing on metastatic disease control.

Main Methods:

  • Review of clinical experience and reported treatment responses.
  • Discussion of biological phenomena related to micrometastasis.
  • Analysis of dose-response relationships in adjuvant therapy.

Main Results:

  • Clinical data suggests that lower radiation doses (less than 45-50 Gy) can achieve significant reductions in metastasis incidence.
  • Early initiation of adjuvant therapy is crucial for improved outcomes.
  • Normal tissue tolerance can necessitate the acceptance of lower doses.

Conclusions:

  • Biological understanding of micrometastases can refine adjuvant therapy strategies.
  • Lower radiation doses are viable for treating subclinical disease, particularly when treatment is timely.
  • Balancing efficacy with normal tissue tolerance is key in optimizing adjuvant radiation therapy.

Related Experiment Videos